Kringle Pharma,Inc. Logo

Kringle Pharma,Inc.

4884 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号彩都バイオインキュベータ207号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company dedicated to advancing regenerative medicines through the development of innovative therapies based on recombinant human HGF (Hepatocyte Growth Factor). Focused on treating intractable and rare diseases, Kringle Pharma is conducting clinical trials to harness the protective and regenerative properties of HGF protein. The company's robust manufacturing capabilities ensure the production of high-quality pharmaceutical-grade HGF, positioning it as a leader in the field. By promoting the development of therapeutic agents aimed at addressing unmet medical needs, Kringle Pharma aims to transform the lives of patients globally, offering hope where few treatment options exist.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Kringle Pharma,Inc.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-16 09:00
Prospectus
有価証券届出書(組込方式)
Japanese 364.6 KB
2025-05-12 08:41
Regulatory News Service
確認書
Japanese 8.2 KB
2025-05-12 08:40
Interim Report
半期報告書-第24期(2024/10/01-2025/09/30)
Japanese 181.3 KB
2024-12-23 06:32
Regulatory News Service
臨時報告書
Japanese 24.0 KB
2024-12-23 06:31
Regulatory News Service
確認書
Japanese 8.2 KB
2024-12-23 06:30
Annual Report
有価証券報告書-第23期(2023/10/01-2024/09/30)
Japanese 2.2 MB
2024-12-23 06:30
Regulatory News Service
内部統制報告書-第23期(2023/10/01-2024/09/30)
Japanese 21.7 KB
2024-08-26 03:25
Regulatory News Service
臨時報告書
Japanese 22.4 KB
2024-05-13 08:40
Quarterly Report
四半期報告書-第23期第2四半期(2024/01/01-2024/03/31)
Japanese 179.6 KB
2024-05-13 08:40
Regulatory News Service
確認書
Japanese 8.2 KB
2024-02-09 07:41
Regulatory News Service
確認書
Japanese 8.2 KB
2024-02-09 07:40
Quarterly Report
四半期報告書-第23期第1四半期(2023/10/01-2023/12/31)
Japanese 139.3 KB
2023-12-25 08:24
Regulatory News Service
臨時報告書
Japanese 22.3 KB
2023-12-25 08:23
Regulatory News Service
確認書
Japanese 8.2 KB
2023-12-25 08:22
Regulatory News Service
内部統制報告書-第22期(2022/10/01-2023/09/30)
Japanese 21.6 KB

Automate Your Workflow. Get a real-time feed of all Kringle Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kringle Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK